AngioDynamics (NASDAQ:ANGO) Hits New 1-Year High – What’s Next?

AngioDynamics, Inc. (NASDAQ:ANGO)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as $13.50 and last traded at $13.5390, with a volume of 49563 shares changing hands. The stock had previously closed at $13.37.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, November 28th. Canaccord Genuity Group increased their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Price Performance

The firm has a 50-day simple moving average of $11.82 and a 200-day simple moving average of $10.50. The firm has a market capitalization of $555.38 million, a PE ratio of -17.25 and a beta of 0.49.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The firm had revenue of $75.71 million for the quarter, compared to analysts’ expectations of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The business’s quarterly revenue was up 12.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Equities analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Lawrence T. Weiss acquired 10,000 shares of AngioDynamics stock in a transaction dated Tuesday, October 21st. The stock was purchased at an average cost of $11.81 per share, with a total value of $118,100.00. Following the completion of the purchase, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James C. Clemmer bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average cost of $11.15 per share, with a total value of $111,500.00. Following the acquisition, the chief executive officer directly owned 882,529 shares in the company, valued at $9,840,198.35. This trade represents a 1.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 20,890 shares of company stock valued at $239,532. Company insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pier Capital LLC grew its holdings in AngioDynamics by 40.5% during the 2nd quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier’s stock valued at $6,887,000 after buying an additional 200,244 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of AngioDynamics during the first quarter worth $939,000. Cubist Systematic Strategies LLC increased its holdings in AngioDynamics by 71.8% in the 1st quarter. Cubist Systematic Strategies LLC now owns 232,473 shares of the medical instruments supplier’s stock valued at $2,183,000 after acquiring an additional 97,123 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its stake in AngioDynamics by 890.3% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 224,514 shares of the medical instruments supplier’s stock worth $2,227,000 after purchasing an additional 201,843 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of AngioDynamics by 419.1% during the 1st quarter. Deutsche Bank AG now owns 201,897 shares of the medical instruments supplier’s stock valued at $1,896,000 after purchasing an additional 163,002 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.